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Abstract
The role of VEGF during development and in pathology is well known, but its function in normal
adult tissues is poorly understood. Adverse effects associated with the use of anti-angiogenic
therapies targeting VEGF in human pathologies have begun to reveal potential functions of VEGF
in quiescent vasculature. Further clues from expression studies of VEGF and its receptors in the
adult, from the disease preeclampsia, and from experimental neutralization studies, have suggested
that VEGF is involved in endothelial cell survival and fenestration, as well as in the signaling and
maintenance of non-endothelial cells. The various biochemical properties of VEGF, and its
interaction with other growth factors, may be an important point in determining whether VEGF
functions as a maintenance factor versus an angiogenic factor. A thorough understanding of the
function of VEGF in the adult may lead to more efficacious pro- and anti-angiogenic therapies.
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Introduction
Vascular endothelial growth factor (VEGF, VEGF-A or VPF) was first described as a tumor-
derived factor with potent ability to induce endothelial cell permeability [1], proliferation and
angiogenesis [2,3]. Since its initial discovery, VEGF’s action on endothelial cells (EC) has
been expanded to include migration and invasion into the basement membrane, proliferation,
survival and the formation of fenestrations, which has largely been elucidated using in vitro
and in vivo tumor studies. VEGF is biologically active as a homodimer of approximately 40kD,
belonging to a family of secreted glycoproteins, including VEGF- B, C, D and placenta growth
factor (PlGF). During development, VEGF expression initiates prior to gastrulation [4], and is
important in both vasculogenesis, the process by which blood vessels develop de novo from
endothelial cell precursors, and angiogenesis, in which blood vessels sprout from existing blood
vessels [5,6]. Deletion of either a single or both alleles of the VEGF gene in mice results in
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embryonic lethality by E9.5 and E10.5 with severe vascular abnormalities [7,8]. Furthermore,
overexpression of VEGF also results in embryonic lethality [9]. These observations underscore
the importance of proper regulation of VEGF expression for normal development to occur.
VEGF signaling is mediated via two receptors: VEGFR1/Flt1 and VEGFR2/Flk1; homozygous
mutation of either of these receptors results in embryonic lethality [10–12]. In addition, two
co-receptors for VEGF, neuropilin-1 and 2 (Nrp-1 and Nrp-2) [13,14], are also required
embryonically [15,16]. The relative contributions of the various VEGF receptors on VEGF
signaling in different endothelial cell beds are still not well understood.
While extensive research has shown that VEGF is crucial for developmental, physiologic and
pathologic angiogenesis, whether it is required in the adult is not well understood. Early studies
of genetic VEGF targeting [8,17] and neutralization studies in tumorigenic mice [18] suggested
that VEGF is not required in the adult as these adult mice showed no obvious phenotype,
making it an attractive target in many diseases. As a result, a wealth of pharmacologic agents
have been designed to target either VEGF or its receptors. Though beneficial effects have been
observed, the presence of consistent significant side effects suggests that VEGF is important
in the maintenance of quiescent vasculature and non-vascular tissues. This review discusses
the expression of VEGF and its receptors in adult tissue, VEGF association with fenestrated
vasculature, VEGF effects on non-vascular cells, conditions and factors that may affect VEGF
action, and implications for manipulating VEGF in disease treatment.
VEGF expression in the adult
VEGF is robustly expressed embryologically, and is critical for proper blood vessel formation,
but its expression is also important in the adult in mediating physiologic angiogenesis during
the female reproductive cycle in the uterus, ovary and breast [19,20], in wound healing [21,
22], in bone repair [23] and in skeletal muscle in response to exercise [24]. VEGF is also
upregulated and involved in pathophysiologic processes such as in rheumatoid arthritis [25,
26], psoriasis [27], atherosclerosis [28], amyloid lateral sclerosis (ALS) [29], age-related
macular degeneration (AMD) [30,31], diabetic retinopathy [32,33], retinopathy of prematurity
[34], sepsis [35] and tumor angiogenesis [36,37]. Although VEGF is required for postnatal
processes that involve angiogenesis, little is know about its potential role in quiescent vascular
beds.
Some insight into VEGF’s potential role in the adult comes from the analysis of its expression
pattern. VEGF is expressed in virtually every tissue in the adult [38–47]. A systematic study
of VEGF expression in the adult using VEGF-lacZ mice [46], revealed that specific subsets of
cells in each tissue express VEGF. Three general patterns of expression were observed, which
may provide information to the role of VEGF in those tissues (Table 1). In regions with sparse
cellular VEGF expression, VEGF was expressed primarily by pericytes and vascular stromal
cells. During blood vessel maturation, pericytes are differentiated from mesenchyme and
become tightly associated with EC, an event associated with blood vessel maturation.
Coincident with their differentiation, pericytes begin to synthesize VEGF, which mediates, at
least in part, capillary stabilization [48]. In tissues including the retina (Figure 1a), brain and
testes, the vasculature is characterized as having barrier function (retinal-blood barrier, blood-
brain barrier, testis-blood barrier); interestingly, relatively few cells express VEGF in these
organs, and it is possible therefore that the relatively low expression of VEGF contributes to
the impermeability of these vessels. In addition to its putative role as an endothelial survival
factor, there is recent evidence to support a role for VEGF as a tropic factor for retinal neurons
[49].
In the tissues with an intermediate number of cells expressing VEGF, such as in cardiac and
skeletal muscles, most myocytes appeared to express VEGF (Figure 1b). As these tissues are
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physiologically dynamic and have the capacity to hypertrophy with training, VEGF may act
to support the rich vasculature of the muscle [50, 51], depending on the physiologic requirement
of the muscle.
The highest density of VEGF expressing cells was found in tissues with fenestrated vasculature
and was localized to the epithelia in contact with fenestrated vessels. Tissues, whose
microvasculature is fenestrated, have secretory and/or filtration functions, for example the
glomerulus (urine filtrate), choroid plexus (Figure 1d) (cerebrospinal fluid production),
pancreas (exocrine and endocrine secretions) and liver (filtration and secretion). Thus, VEGF
in these tissues may mediate both survival and maintenance of the fenestrated state of the EC.
Though ECs are the main target of VEGF, they do not generally express VEGF [52], but instead
respond to VEGF secreted in a paracrine manner. It is speculated that expression of both the
receptor and ligand in EC would lead to a dangerous positive feedback, resulting in
overproliferation, such as is observed in hemangiomas [53] and in tumorigenesis [54]. One
exception to this appears to be in the largest blood vessel, where aortic EC, but not inferior
vena cava EC, express VEGF (Figure 1e, f, respectively)[46]. The mechanism or function of
VEGF expression in the aortic EC is currently unknown.
Although VEGF binds to VEGFR1, VEGFR2, Nrp-1 and Nrp-2, its main signaling receptor
in the endothelium is VEGFR2. VEGFR2 belongs to the family of receptor tyrosine kinases
[55] (reviewed in [56]), and upon VEGF binding, there is dimerization and activation of the
tyrosine kinase, resulting in phosphorylation of specific tyrosine residues on the cytoplasmic
tail, which in turn promotes docking of signal transducing molecules. Several key tyrosine
residues have been identified, and activation of specific residues leads to different downstream
effects. Of these residues, Tyr 1175 is implicated in endothelial survival and permeability,
though not exclusively [57], through the PI3-K/AKT pathway [56,58]. Signaling via residue
Tyr 951 is also involved in vascular permeability [59]. Although VEGFR1 is also expressed
by EC, it is believed to act primarily to modulate VEGFR2 signaling. Evidence for this concept
comes from observations that although targeted disruption of VEGFR1 signaling results in EC
overgrowth and vascular disorganization [10,60], mice in which the intracellular kinase
domains of VEGFR1 was deleted have no obvious vascular phenotype [61]. Recent evidence
has suggested that VEGFR1 can anchor VEGF to the cell-surface, allowing increased
interaction with VEGFR2 [62].
For VEGF to exert an effect in the adult, its receptor also has to be expressed in close proximity
to the VEGF source. Several recent reports have demonstrated that VEGFR2 is expressed and
activated in adult tissue [46,47,63,64] (Figure 1g, h), giving further evidence that VEGF plays
a biologic role in the adult.
Implications of the role of VEGF in the adult from clinical observations
A. Side effects from clinical systemic VEGF neutralization
All cells require oxygen, and due to the limits of oxygen diffusion, cells more than 100 μm
away from blood vessels become oxygen deprived. For this reason, solid tumors are restricted
to a size of 3–4 mm in diameter without neovascularization. The discovery of a tumor-secreted,
angiogenic factor [65], which was later identifed as VEGF [3], and was hypoxia-inducible
[66], led to the concept that neutralization of VEGF could block tumor-induced blood vessel
growth, thus inhibiting tumor growth and metastasis [67]. Early reports suggested that VEGF
was not important in microvascular homeostasis [8,17], and thus VEGF became an attractive
target for anti-angiogenesis; it was believed that VEGF neutralization would specifically target
the tumor microvasculature without affecting non-diseased vascular beds, thus circumventing
side effects associated with standard chemotherapy. This model has now been also applied to
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other VEGF-mediated diseases, and has led to the implementation of therapies for ocular
vascular proliferative diseases as well [68].
As an anti-tumor agent, clinical development of many agents that target either VEGF or its
receptors (see [69] for a detailed list of agents) are in progress. The first FDA-approved anti-
VEGF therapy, bevacizumab (Avastin™, Genentech) was introduced into the clinics in 2004
in combination with Irinotecan, fluorouracil, or leucovorin for the treatment of metastatic
colorectal cancer (mCRC) [70] and more recently for the combination treatment of advanced
non-small-cell lung cancer [71]. Subsequently, Avastin is now being clinically tested as a
mono- or combination therapy agent for the treatment of cancers in almost every organ system
[72], with many in either Phase III or IV. Clinical positive effects of Avastin treatment in mCRC
and lung cancer include a marked tumor regression and increase in median survival as well as
improvement in long-term survival in some patients [73].
Common side effects of Avastin treatment have been noted including hypertension, proteinuria,
bleeding and impaired surgical wound healing [70,71,74]. Infrequent, but life-threatening
complications have been reported as well, including, arterial thrombosis [75,76],
gastrointestinal perforation [77], and reversible focal posterior leukoencephalopathy (RFLP)
[78–80] (Figure 2).
In addition to targeting the VEGF ligand, another approach of anti-VEGF therapy is to target
its receptors [81]. Several drugs targeting VEGF receptors have been FDA approved, including
sunitinib (Sutent™, Pfizer) for the treatment of advanced renal cell carcinoma [82,83] and
gastrointestinal stromal tumors [84] and sorafenib (Nexavar, Bayer/Onyx Pharmaceuticals) for
the treatment of clear-cell renal cell carcinoma [85]. Side effects similar to those noted with
Avastin have been reported; however, these drugs have several additional side effects probably
due to the effects on other receptor tyrosine kinases. Although these drugs selectively block
VEGFR2 and VEGFR1, there is significant inhibition of other receptors as well, due to the
homology of these receptors, including VEGFR3, PDGFRs, and receptor kinases associated
with KIT, and RET receptor kinases [84,85].
The reproducible side effects related with these drugs indicate that VEGF neutralization in
quiescent tissue does in fact influence tissue function. Furthermore, the incidence and severity
of side effects associated with VEGF blockage may provide insight to VEGF-sensitive tissues
and VEGF-dependent processes in the adult.
B. VEGF neutralization in the pathogenesis of preeclampsia
Recent evidence from the disease preeclampsia has also begun to provide evidence concerning
the role of VEGF in the adult. Preeclampsia (reviewed in [86]), a disease of pregnancy, affects
5–7% of women in their 2nd and 3rd trimester, and is marked by hypertension, edema and
proteinuria. The pathology is caused by systemic endothelial dysfunction, and if left untreated,
ascites, pleural edema, thrombocytopenia, headaches, disseminated intravascular coagulation,
and blindness can occur. In severe cases, there is progression to eclampsia, characterized by
seizures, and other neurologic manifestations including strokes.
Because delivery of the placenta results in immediate improvement and cessation of most
symptoms, it was hypothesized that the placenta was the source of the insulting agent. Several
factors were found to be over expressed by preeclamptic placentas, including soluble VEGFR1/
sFlt1, which is found at high levels in the blood of preeclamptic mothers [87–89]. sFlt1 is
produced by alternative splicing of the Flt1 transcript, resulting in a deletion of the intracellular
and transmembrane domains of Flt1, rendering the truncated protein soluble. sFlt includes 85%
of the extracellular domain, plus 30 amino acids from the 13th intron [90]. sFlt1 binds VEGF
with an affinity 10-fold greater than VEGFR2, thus acting as a soluble trap of VEGF [91,92].
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sFlt1 can also heterodimerize with VEGFR2 acting in a dominant negative manner [93].
Systemic administration of sFlt1 to pregnant rats recapitulates several, but not all symptoms
of preeclampsia, including hypertension and proteinuria [87]. In addition to proteinuria and
hypertension, reversible posterior leukoencephalopathy, a severe complication of
preeclampsia, has also been seen in patients on Avastin [94]. The parallel between these
hallmarks of preeclampsia and the side effects of Avastin support the concept that VEGF is
involved in vasculature maintenance. Although hypertension, which is common to both
preeclamptic and Avastin patients, has been suggested to be the basis of the
leukoencephalopathy, it has also been suggested that primary insult to brain endothelium may
also contribute to this condition. However, this has not been studied, and remains an interesting,
unanswered question.
Role of VEGF in the adult
A. Vascular stability
While therapeutic VEGF neutralization and preeclamspia have revealed potential roles for
VEGF in the adult, experimental studies in rodents have begun to unravel the nature of VEGF
function in quiescent tissues. Inhibition of VEGF or its receptors has been shown to lead to
alteration of the microvasculature as well as vessel regression in a number of tissues. In the
kidney this resulted in glomerular endotheliosis and proteinuria (Figure 3c, f) [87, 95], whereas
in the lung alveolar apoptosis and enlarged airspaces were observed (Figure 3a, d) [96, 97].
Vessel regression was also noted in the pancreas [98, 99], trachea [98, 100], thyroid (Figure
3b, e) [98], and small intestine [98]. Interestingly, there were no apparent alterations in the
microvasculature of heart, musculature of the tongue, or brain [98]. In addition to microvascular
regression, hypertension was a common finding, and may be the direct result of disrupting
vascular NO-mediated tone [87, 101]. Alternatively, it may be secondary to kidney injury or
to destruction of microvasculature (rarefaction), resulting in increased systemic resistance.
The blood vessel regression and tissue dysfunction observed in these experiments are
presumably due to interference with the trophic effect of VEGF on endothelial survival [100,
102]. The cascade of events likely begins with local thrombosis and decreased vascular
perfusion, leading to endothelial cell apoptosis [102]. Basement membrane “sleeves” with
pericytes devoid of EC [98] persist for a period of time, and can be recanalized by EC if
neutralization is reversed. Neutralization of VEGF for seven days followed by seven days of
reversal resulted in almost complete revascularization [103]. That short inhibition of VEGF
may result in regrowth of vessels following cessation of VEGF inhibition, may provide a
challenge in anti-VEGF therapies. Conversely, the vestigial presence of the basement
membrane ghost in tissues such as infarcted brain and heart tissue, may allow targeted delivery
of VEGF to efficiently stimulate new blood vessels.
B. Effects of VEGF on non-vascular cells
VEGF, like other growth factors (e.g. hepatocyte growth factor and fibroblast growth factor)
was so named because of initial observations demonstrating EC as its target. However, VEGF
may act on other cell types based on the presence of either VEGFR1 or VEGFR2 on those
cells. In addition, several reports have demonstrated the action of VEGF on monocytes [104,
105], macrophages [106], mast cells [107], eosinophils [108], dendritic cells [109],
megakaryocytes [110], lymphocytes [111], hematopoeitic stem cells/bone marrow-derived
circulating cells [112–115], type II lung alveolar epithelial cells [116] and lens epithelium
[117]. VEGF has been shown to mediate the survival of hematopoeitic stem cells, neuronal
cells, neuronal stem cells and lymphocytes; the differentiation of megakaryocytes and dentritic
cells; and, to mobilize bone marrow precursor cells. In addition to its direct effects on
Maharaj and D’Amore Page 5
Microvasc Res. Author manuscript; available in PMC 2008 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
endothelial cells during angiogenesis, VEGF also influences angiogenesis via recruitment of
bone marrow endothelial cell precursors and inflammatory cells.
Observations from the therapeutic use of anti-VEGF, as well as from preeclampsia, also
provide evidence regarding the action of VEGF on non-endothelial cells. Findings of
thrombocytopenia and neutropenia [69,74,118] are consistent with a role for VEGF in the
regulation of platelet and leukocyte production. Gastroperforation and impaired wound healing
likely result from impaired immune cell function and angiogenesis.
VEGF is also involved in lymphangiogenesis [119–121]. Although its function in lymphatic
maintenance is unknown, edema in preeclamptic patients [86] may be due, at least in part, to
lymphatic destruction besides decreased osmotic pressure, and warrants further study.
In addition to its action on vascular and immune cells, increasing evidence points to a role for
VEGF in neuronal growth and survival. VEGF acts on neuronal cells [49,122,123] and neuronal
stem cells [124] in vitro and in vivo. In the eye, both neuronal and glial cells express VEGF
receptors [125]; addition of VEGF120 following ischemic/reperfusion injury resulted in
neuroprotection of retinal ganglion cells and of cells in the inner nuclear layer (Figure 4)
[126]. Pathologically, low levels of VEGF are associated with motor neuron degeneration
[127], and are implicated as a modifier in amyotrophic lateral sclerosis in humans and mice
[29,128] and Alzheimer’s disease in humans [129]; experimental delivery of VEGF acts to
prolong neuron survival in the ALS mice [130]. Although not examined experimentally,
peripheral neuropathy associated with Avastin, reversible focal posterior leukoencephalopathy
in both Avastin-treated and preeclamptic patients, as well as seizures in eclamptic patients, are
consistent with a neuro-protective role for VEGF [131].
C. VEGF and fenestrations
VEGF was first identified as a potent vascular permeability factor [1]. Permeability is important
in many physiologic processes such as in glomerular filtration, cerebrospinal fluid production,
liver blood filtration, and endocrine secretion into the blood stream [132], is central to wound
healing [21], and exacerbates tumors by promoting ascites and edema. Endothelial cell
permeability is mediated via both VEGFR1 and VEGFR2 [56], resulting in the formation of
transcellular gaps, vesiculovacuolar organelle formation, and fenestrations [133]. Fenestrae
are endothelial cell plasma membrane specializations that appear as circular discontinuities
approximately 60 nm in diameter and facilitate movement of particles in and out of the
circulation. Fenestrated EC are found in most endocrine tissues [132] as well as in the kidney
glomerulus, choroid of the eye, choroid plexus, gastrointestinal tract and in tumor vessels. In
each of these tissues VEGF expressing cells are found in close juxtaposition to the underlying
fenestrated microvasculature (Figure 1d) [46].
VEGF has been shown to be involved in the induction of fenestrae formation in vitro [134–
136], but the mechanism of fenestrae formation and maintenance in the adult is not well
understood. One link that has been made between VEGF and fenestrae is the regulation of the
caveolar protein plasmalemmal vesicle-associated PV-1 protein [137] [138]. However, not all
fenestrations are diaphragmmed, so PV-1 may not be the only mediator of VEGF and
fenestrations.
Although all fenestrated tissue contain VEGF expressing cells, not all tissue with VEGF
expressing cells are fenestrated. There are several possible explanations for this observation.
Although VEGF may be important for inducing and maintaining fenestration, other factors
may be required along with VEGF for fenestrations. For instance, leptin has been shown to act
synergistically with VEGF to induce fenestrations [139]. Whether leptin is expressed in all
fenestrated tissues, is to be determined. These ‘co-factors’ may not be present in all tissue, even
Maharaj and D’Amore Page 6
Microvasc Res. Author manuscript; available in PMC 2008 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
if VEGF is present, thus not allowing fenestrations. Conversely, some tissues may even produce
factors to prevent permeability [140]. Another likely possibility is that the induction of
fenestrations may simply be a dosage effect, with tissues that display fenestrated capillaries
expressing higher levels of VEGF than tissues without fenestrated endothelium.
Several studies have demonstrated that VEGF neutralization in tumors in vivo leads to a
diminution of fenestrations [102]. Tumors are often edematous, and it has been postulated that
high interstitial pressure may make the delivery of chemotherapy to tumor cells inefficient.
Therefore, reducing tumor vessel permeability may have therapeutic advantages in cancer
treatment, allowing normalization of tumor vasculature and more efficient delivery of
chemotherapy [69,141]. However, systemic VEGF neutralization has also been reported to
affect non-tumor fenestrated vasculature, including the thyroid, pancreas and glomerulus
[98].
Biochemical, molecular and cellular factors affecting VEGF signaling in vivo
Although VEGF is constitutively expressed in the adult, and is a potent angiogenic factor, it
does not result in widespread angiogenesis in resting tissue. The discovery of multiple pro-
angiogenic and endogenous anti-angiogenic factors [142] with overlapping expression patterns
indicates that angiogenesis is dependent on a balance between pro- and anti- angiogenic factors.
In addition to countering the action of local angiogenic factors in quiescent tissue, endogenous
factors maintain the avascularity, for example, chondromodulin-I acting in cardiac valves
[143] and sFlt-1 in the cornea [144,145]. VEGF signals via several receptors and co-receptors,
and via multiple signaling pathways [56,146]. Thus, whether VEGF signaling leads to
permeability, proliferation, migration, or survival, may therefore depend on the signaling
pathway components, effective tissue concentration as well as on the action of other factors.
VEGF expression in the adult is cell-type specific [45,46] and is controlled at many levels from
transcription [147] to translation [148], and is upregulated in tumors and in various pathologic
states. One of the best-characterized stimuli of VEGF transcription is hypoxia, which acts by
stabilization of the hypoxia-inducible factor-1 alpha (HIF1α) transcription factor [149].
Hypoxic regulation of VEGF also takes place post-transcriptionally via mRNA stabilization
[150](reviewed in [151]). VEGF expression is induced by other growth factors and cytokines
including IGF-1, Il-6, Il-1, PDGF, TNF-α, TGF-β and FGF-4 [152,153]. In addition, VEGF
expression is also stimulated by physical forces, including stretch [50,154], with one putative
transcription factor being the Kruppel like factor-2 [155]. Analysis of the VEGF promoter
reveals many other potential transcription factor responsive elements [149], of which several
pathways have been elucidated, for example EGF [156] and HGF signaling [157] via the SP1
responsive element (for an extensive list see [149]).
Alternative splicing of VEGF mRNA results in various isoforms, which include VEGF121,
VEGF145, VEGF165, VEGF189 and VEGF206, in humans and VEGF120, VEGF164 and
VEGF188 in mice. These isoforms display tissue-specific patterns of expression [45]. Studies
of genetically engineered mice expressing only one VEGF isoform indicate that VEGF
isoforms have distinct yet some overlapping roles in vascular development and function as
evidenced by tissue-specific vascular defects in these mice [158]. The VEGF isoforms display
differences in their biochemical properties, including receptor binding with VEGF165 and
VEGF188 but not VEGF120 binding to neuropilins and heparan sulfate. The differential
affinity to heparan sulfate is important in their binding to VEGFR1 and VEGF2 as heparan
sulfate can mediate the binding and transactivation of these receptors [159]. Furthermore,
differential binding to heparan sulfate is reported to lead to different VEGF actions, including
endothelial cell survival, adhesion and vascular branch formation [160,161]. Both VEGF164
and VEGF188 bind heparan sulfate, making them partially or fully cell-bound, respectively,
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whereas VEGF120 does not bind heparan sulfate, and is freely diffusible [162]. A newly
identified splice variant of VEGF, VEGF165b, is postulated to have an inhibitory effect on
angiogenesis [163].
VEGF, a secreted glycoprotein, is subject to a variety of extracellular modifications that have
direct effects on its biochemistry and bioavailability. In addition to alternative splicing, VEGF
variants arise from proteolytic processing (reviewed in [21]), which leads to differences in
biologic effects. For instance, cleavage of VEGF189 by urokinase, allows it to more potently
bind to VEGFR2 [148]; plasmin digestion of VEGF165 results in two fragments, one with and
one without a heparin binding domain [164], while cleavage of VEGF by various
metalloproteinases results in different cleavage products with different outcomes on vascular
morphogenesis [165].
VEGF exerts its action via binding to VEGFR1, VEGFR2, Nrp-1 and Nrp-2. Whereas binding
of VEGF to Nrps enhance VEGF’s action [166], binding to VEGFR1 results in a diminution
of VEGF availability. Therefore, it is possible that the tissue ratios of VEGFR1:VEGFR2
determine the tissue’s angiogenic status. For instance, under hypoxic conditions, when VEGF
is upregulated, concomitant upregulation of VEGFR1 [167], may act to modulate VEGF
signaling.
Implications for therapeutic manipulation of VEGF
The role of VEGF in development and pathology is well known and emerging evidence points
to a role for VEGF in the maintenance of quiescent tissues. Knowledge of adverse-effects
associated with anti-VEGF therapy, observations from preeclampsia, and experimental
blockade of VEGF in animal models have exposed tissues and vascular beds sensitive to VEGF
neutralization and revealed potential limitations of current anti- therapy. One of the most
frequently observed side effects of VEGF neutralization is hypertension [74,87]. However, this
issue can be pharmacologically managed, allowing continued patient treatment. Similarly, the
knowledge of increased risks for other side effects such as impaired wound healing,
gastrointestinal perforation, and arterial thrombosis allows careful monitoring of the patient to
avoid serious consequences.
In addition to observations from experimental and clinical observations of VEGF, important
information about additional roles for VEGF can be garnered from clinical observations in
which low VEGF levels are associated with tissue dysfunction, including observation of
alopecia in humans with loss of VEGF in hair follicles [168], decreased VEGF in the aged
cochlea [169], and reduced VEGF associated with thyroid cartilage ossification [170]. Another
interesting recent report that warrants careful clinical monitoring is an association of increased
erythropoiesis with VEGF neutralization [171], as polycythaemia can lead to high blood
viscosity and an increased risk for thrombosis. As studies reveal other functions of VEGF in
the adult, clinicians should be able to incorporate this information into their clinical follow-
up.
Understanding side effects and biologic effects of VEGF neutralization can also provide useful
surrogate markers of therapeutic efficacy. Some of the markers currently being investigated
include protein levels in plasma (e.g. VEGF) [172,173] and urine [174], circulating endothelial
progenitor cells [175,176], and wound healing time [177].
Systemic side effects may also be minimized by local or targeted delivery of anti-VEGF
therapies. VEGF-A is a major mediator of pathologic angiogenesis in the eye and is associated
with diseases such as age-related macular degeneration (AMD) [31] and proliferative diabetic
retinopathy [33]. As in tumors, VEGF is upregulated in these ocular diseases and is, thus, a
useful potential therapeutic target (reviewed in [30,68]). Two VEGF inhibitors, pegaptanib
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(Macugen™; OSI/Pfizer) [178] and ranibizumab (Lucentis™, Genentech) [179] have been
approved by the FDA for intra-ocular use in AMD, and Avastin has been utilized intraocularly
off-label for the treatment of AMD as well [180]. For this approach however, a primary
consideration will be potential effects that may arise from high local delivery. As stated in
Section B, VEGF is involved in lens signaling [117], choroid maintenance [47] and retinal
neuronal maintenance [125].
As these drugs are delivered intravitreally, the potential for systemic side effects should be
minimized, and have indeed resulted in minimal systemic side effects [68]. However, these
medications appear to have the potential to inhibit VEGF systemically as intraocular injections
of Lucentis in Rhesus monkeys have resulted in systemic serum levels of approximately 150
ng/ml following bilateral injection of 500 μl of the drug with a half life of 3.5 days [181]. This
circulating level may be able to sequester plasma VEGF and act locally in tissue, and may be
causal for increased incidences of arterial thromboembolic events in patients treated with
Lucentis [182].
A better understanding of the role of VEGF in the adult may also lead to therapies aimed at
stimulating blood vessel growth or tissue growth in damaged tissue. Pro-angiogenic therapy
using VEGF may be useful in ischemic diseases such as stroke [183], myocardial ischemia and
coronary artery disease [184–186], peripheral neuropathy [187], wound [21] and fracture
healing [188], Alzheimer’s disease [129] and ALS [122,123]. However, delivery of VEGF will
have to be approached carefully to avoid a systemic VEGF increase [189] because shifting the
balance between endogenous angiogenesis inhibitors and stimulators may lead to aberrant
vessel growth and/or exacerbation of existing diseases. Support for this comes from studies in
which overexpression of VEGF in mouse podocytes leads to collapsing glomerulopathy [95],
and in which VEGF overexpression in the skin results in inflammation [163]. In clinical trials
using VEGF therapy, lower extremity edema and hypotension was observed [190], likely
attributable to increased vascular permeability.
The manipulation of VEGF has allowed for therapies that lead to significant improvement in
survival in cancer, vision in AMD, cardiac function in heart disease, and is currently in clinical
and experimental trials in the treatment of many more diseases. Elucidating the role of VEGF
in the adult should permit the development of strategies that effectively target the disease, while
minimizing side effects and morbidity.
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Figure 1. Expression of VEGF and its receptors in the adult
VEGF expression is shown in adult VEGF-lacZ mice, which make a nuclear localized β-
galacotosidase (β-gal) protein wherever VEGF is expressed. Blood vessels, where shown, were
identified by immunohistochemistry using the pan-endothelial cell marker- CD31
(arrowheads). VEGF expression in the pericytes in retina (A, arrows), cardiac myocytes (B),
choroid RPE layer (C, arrows), choroid plexus epithelium (D, arrows) overlying fenestrated
blood vessels (D, arrowheads), aortic endothelium (E, arrows), inferior vena cava medial layer
cells (F, arrows). VEGFR2 expression and activation in adult tissues as identified by (G)
western blot for VEGFR2 of protein lysates from liver, kidney, adipose and lung (bottom panel)
and for phosphorylated VEGFR2 (top panel) and by (H) immunohistochemistry of aorta for
phosphorylated VEGFR2 (arrows). Abbreviations (C): ONL, outer nuclear layer, OS, outer
segment, RPE, retinal pigmented epithelium, Chd, choroid. Reprinted from IOVS 2006, 47:
3135–3142 (C), Am J Pathol 2006, 168: 639–658 with permission from the American Society
of Investigative Pathology (B, D–H), unpublished data D’Amore lab (A).
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Figure 2.
MRI FLAIR image showing focal lesions (arrows) associated with reversible focal
leukoencephalopathy in a patient on Avastin. Taken with permission from N Engl J Med (2006)
354; 980–982, Copyright © 2006 Massachusetts Medical Society
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Figure 3. Role of VEGF in vascular stability
Administration of SU5416, a tyrosine kinase inhibitor with selective inhibition of VEGFR, to
rats by bronchiolar delivery results in enlargement of air spaces, indicative of emphysema (D)
compared to vehicle (A). Adenoviral delivery of sVEGFR1 to adult mice (B, E) results in
decreased vascular density in the thyroid (E) compared to vehicle delivery (B), and
endotheliosis in the glomerulus in the kidney in pregnant rats (F) compared to vehicle delivery
(C). Taken with permission from J Clin Invest (2000) 106; 1311–1319 (A, D), Am J Physiol
Heart Circ Physiol (2006): H560-H576 (B, E), and J Clin Invest (2003) 11; 649–658 (C, F).
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Figure 4. Neuroprotective role of VEGF in the eye
Addition of VEGF120 after 60 min of ischemic/reperfusion injury resulted in decreased cell
death in the ganglion cell layer (GCL), and inner nuclear layer (INL) after 14 days (C) compared
to addition of PBS only (B). Taken from Nishijima et al. AJP 2007 (IN PRESS) with permission
from the American Society of Investigative Pathology.
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Table 1
Pattern of VEGF expression in the adult
Sparse cellular expression Intermediate cellular expression Dense cellular expression
Cellular Source Vascular stromal cells: pericytes and smooth muscle cells Non-vascular mesenchymal cells Epithelial cells directly abuting capillaries
Examples Brain parenchymal cells, pericytes, retinal pericytes, Leydig cells Skeletal myocytes, cardiac myocytes Glomerular epithelium, choroid plexus epithelium, serous salivary epithelium, pancreatic β-islet epithelium, retinal pigmented epithelium
Microvasculature Characteristics High resistance endothelium (blood-brain-barrier, retinal-blood-barrier, testis-blood-barrier) Dynamic capillaries responsive to demands of tissue. Highly leaky vessels- fenestrated vessels in endocrine organs, and sinusoidal vessels in liver
Postulated Function of VEGF on Endothelial cells Endothelial cell survival EC survival, dynamic angiogenesis EC survival, maintenance of fenestrations and sinusoids
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